News and Events

News

Apr 29, 2025

MMIT Announces Winners of the Tenth Annual Specialty Pharmacy Patient Choice Awards

Yardley, PA – April 29, 2025 – Today Managed Markets Insight & Technology (MMIT), the pharmaceutical industry’s trusted partner for overcoming barriers to patient access, announced the winners of its tenth annual Specialty Pharmacy Patient Choice Awards.

Mar 20, 2025

MMIT Announces Finalists of the Tenth Specialty Pharmacy Patient Choice Awards

Yardley, PA – March 20, 2025 – Managed Markets Insight & Technology (MMIT), the pharmaceutical industry’s trusted go-to-market partner for overcoming barriers to patient access, has announced the finalists of its tenth annual Specialty Pharmacy Patient Choice Awards. MMIT’s real-world data and expertise helps pharmaceutical manufacturers better understand how patients move from diagnosis to treatment.

Mar 18, 2025

Norstella Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025

New York – October 18, 2025 – Norstella, a leading global provider of pharma intelligence solutions, is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones in all sectors of the economy.

View All

Meet with MMIT at Upcoming Events

June 26 - 27 | Philadelphia, PA

EVIDENCE 360: RWE, Pricing & Reimbursement Summit USA

The EVIDENCE 360: RWE, Pricing & Reimbursement Summit USA is a groundbreaking two-day event dedicated to advancing the role of Real-World Evidence (RWE) in shaping healthcare policies and market access strategies. By providing actionable insights and fostering connections among industry leaders, this summit will serve as a catalyst for innovation in healthcare decision-making.

MEET WITH MMIT

October 27 - 30 | National Harbor, MD

AMCP Nexus

AMCP Nexus attracts more than 3,000 member and non-member managed care decision-makers. Attendees include individuals from health plans, PBMs, biopharmaceutical companies, consultants, and other leaders working within managed care pharmacy.   Enjoy education sessions, attend industry workshops, and experience the Expo where exhibitors will showcase the latest innovations and newest products.

In the Media

TechTarget

How Oral GLP-1 Drugs Could Disrupt the Weight Loss Market

June 11, 2025

The advent of FDA-approved oral formulations of GLP-1 weight loss drugs could reshape how obesity is treated in America. TechTarget reached out to Jayne Hornung, MMIT’s CCO, for her thoughts on how oral GLP-1s might impact patient access, payer and employer coverage strategies, and the competitive landscape.

Investors Business Daily

Investor’s Business Daily

Novo Nordisk Is Shedding Muscle in the Weight-Loss Brawl With Eli Lilly

May 29, 2025

While Novo Nordisk’s GLP-1s Ozempic and Wegovy are still outselling Eli Lilly’s GLP-1s, Mounjaro and Zepbound, the company is rapidly losing market share. Investor’s Business Daily asked Jayne Hornung, MMIT’s CCO, to comment on lagging insurance coverage for weight-loss drugs and Novo’s recent partnership with Hims to sell Wegovy at a discount.

TechTarget

Biosimilars Set to Surge as Biologic Patents Expire

May 1, 2025

TechTarget taps Steve Callahan, Senior Director of Advisory & Insights at MMIT, to discuss biosimilar pricing, reimbursement, and market share opportunities coming in the next five years. More than 90 biologics—including some blockbuster therapies—are set to lose exclusivity by 2030.

Wired

Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs

April 23, 2025

Can mass produced medicines be considered personalized and compounded? Wired taps Jayne Hornung, MMIT’s chief clinical officer, to comment on Eli Lilly’s lawsuit against four telehealth companies offering off-brand versions of its blockbuster GLP-1 medications Mounjaro and Zepbound.

Investors Business Daily

Investor’s Business Daily

Behind Hims Stock's Roller-Coaster Ride as Weight-Loss Drugs Battle Heats Up

February 28, 2025

With semaglutide no longer in shortage, the future of compounding pharmacies will depend upon their diversification. Investor’s Business Daily reached out to Jayne Hornung, MMIT’s chief clinical officer, for her thoughts on how the FDA’s decision will impact pharmacies.

BioPharma Dive

GSK’s 5-in-1 Meningococcal Shot Wins FDA Approval

February 18, 2025

GSK’s new meningococcal vaccine, Penmenvy, could potentially boost vaccination rates, which have remained low due to a complex vaccine schedule. BioPharma Dive reached out to MMIT clinical advisor Julie Howard for her thoughts on this market disruption.

Forbes

Insurer Denies Access to Drugs Granted Accelerated Approval By FDA

February 3, 2025

One payer’s decision to extend the length of its coverage exclusion period to 18 months for all drugs approved under the FDA’s accelerated approval program has reignited debate on the FDA’s process. Forbes used MMIT’s recent data on payer perception of expedited approvals in this article.

Drug Discovery

Drug Discovery & Development

By 2025, Clinical Research and Patient Care Converge

December 19, 2024

The next year will bring a shift toward real-world applications of AI in the life sciences. Drug Discovery & Development asked MMIT’s Kala Bala and Andrew Rouff to weigh in on data integration, payer behavior, increased competition from biosimilars, and other developments in pharma.

Investors Business Daily

Investor’s Business Daily

The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market

December 5, 2024

The FDA’s decision to remove tirzepatide from its drug shortage list has been criticized by compounding pharmacies, with many claiming patients cannot find either tirzepatide or semaglutide at retail pharmacies. IBD asked MMIT’s Chief Clinical Officer, Jayne Hornung, how patients will be impacted.

Bloomberg Law

J&J, Bristol Myers Turn to Drug Rebates in Fight Over Price Cuts

December 4, 2024

Under the 340B program, manufacturers are required to discount outpatient drugs for covered entities—but how they do this is under debate. Major drug makers are suing for the right to implement a rebate model. MMIT weighs in on the implications of these lawsuits and the need for greater transparency.

Drug Topics

Impact of the Inflation Reduction Act on Biosimilar Pricing, Dispensing

December 3, 2024

On this episode of the podcast Over the Counter, MMIT's Steve Callahan talks with Drug Topics about how future IRA provisions will help biosimilars become a viable and cost-effective alternative to expensive biologics for patients and payers alike.

LISTEN TO PODCAST

Drug Topics

Q&A: The Future of Biosimilar Pricing at the Pharmacy Counter

November 30, 2024

Biosimilars are heavily impacted by the provisions of the Inflation Reduction Act. Drug Topics spoke to MMIT’s Steve Callahan about price negotiation, inflation-based rebates, increased biosimilar reimbursement rates, and the future of biosimilars within the prescription drug market.

Drug Topics

Q&A: A Closer Look at the Current State of Biosimilars in the Drug Market

November 28, 2024

Drug Topics interviews MMIT’s Steve Callahan about the evolution of biosimilars, payer pricing expectations, and the impact of biosimilars on out-of-pocket costs. Callahan explains how real-world data helps pharma understand the market dynamics of successful biosimilar launches.

MM+M

Norstella Rolls Out NorstellaLinQ Data Platform

October 8, 2024

MM+M interviews Norstella CEO Mike Gallup about the launch of NorstellaLinQ, which aggregates and cleans real-world data from various sources to provide comprehensive patient information. Gallup discusses how the incorporation of generative AI and machine learning ensure data consistency and enable a quick response to new data challenges.

Press Release

Norstella Introduces NorstellaLinQ, the Biopharma Industry’s First Fully Integrated Data Asset

October 8, 2024

Norstella unveiled NorstellaLinQ, the biopharma industry’s first and only fully integrated data asset combining both real-world data (RWD) — including open and closed claims, lab results and structured and unstructured electronic medical records (EMR) — with Norstella’s proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data.

Specialty Pharmacy Continuum

What Keeps Pharmacy Stakeholders Up at Night?

August 23, 2024

At Asembia's AXS24 Summit, MMIT's Dinesh Kabaleeswaran and The Dedham Group's Jen Klarer presented on the results of the 2024 State of Patient Access survey. In this article, Specialty Pharmacy Continuum shares key points from their presentation.

Fierce Healthcare

PBMs Defend Business Practices — But Lawmakers Aren’t Convinced

July 23, 2024

The House Committee on Oversight and Accountability held a hearing on the business practices of the three largest PBMs. Fierce Healthcare tapped MMIT’s Andrew Rouff for commentary on the investigation into whether PBMs are responsible for inflating drug prices.

Life Science Leader

Patient Access Challenges Are Changing Pharma Investment Strategies

July 9, 2024

Patient access issues across the value chain are prompting manufacturers to invest in early-stage market access planning using real-world data. MMIT's Dinesh Kabaleeswaran and The Dedham Group's Jen Klarer explain these industry shifts.

InsideHealthPolicy

Safety Concerns Remain Ahead Of FDA Ad Comm On Donanemab

June 10, 2024

Although the FDA is expected to approve Eli Lilly’s Alzheimer’s drug donanemab, concerns remain about the potential for patients to have serious complications. Inside Health Policy tapped MMIT expert Jayne Hornung to share her thoughts on the decision.

M&MM

FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab Under Brand Name Kisunla

June 2, 2024

Eli Lilly's drug will be marketed under the brand name Kisunla for treating adults with early symptomatic Alzheimer’s disease. MM&M asked MMIT's Chief Clinical Officer Jayne Hornung for commentary on this exciting news.

Pharma Executive

Pharmaceutical Executive

Today’s New Messaging Mix: The State of Pharma Marketing in 2024

May 13, 2024

At a Pharmaceutical Executive roundtable event on the state of marketing in the pharmaceutical industry, MMIT's Jay Shah and Skipta's Glen Saunders shared their thoughts on digital strategies, the use of AI, and the impact of med-legal regulations on marketing campaigns.

ISJR Paper

International Journal of Science and Research

Evaluating the Role of AI and Identifying Use-Cases in U.S. Managed Care Organizations

April 2024

This research paper explores how payers’ familiarity with AI tools and explores the likelihood of AI implementation to reduce administrative burden across managed care and government organizations.

Press Release

MMIT Announces Finalists of the Ninth Specialty Pharmacy Patient Choice Awards

March 20, 2024

Managed Markets Insight & Technology (MMIT), the trusted go-to-market partner for overcoming barriers to patient access, has announced the finalists of its ninth Specialty Pharmacy Patient Choice Awards.

Drug Channels

Copay Accumulator and Maximizer Update: Adoption Expands as Legal Barriers Grow

February 14, 2024

This review of current benefit designs uses MMIT’s data on commercial plans’ use of copay accumulators and maximizers.

ISJR Paper

International Journal of Science and Research

Evolving Site of Care Trends in the U.S. Managed Care Ecosystem

January 20, 2024

The movement of care from high-cost, post-acute sites to lower-cost freestanding and non-acute sites has accelerated. This research paper explores the impact of payer site-of-care preferences across payers, oncologists and physicians.

Pharmaceutical Executive

Building Awareness of Anti-Obesity Drugs: 2024 Trends

January 18, 2024

The increased popularity of anti-obesity medications is raising questions about inequities in patient access, due to both shortages and limited payer coverage policies.

Healthcare IT Today

Uses of AI in Healthcare: 2024 Health IT Predictions

January 17, 2024

The application of AI will expand into managed care organizations in the near future. For payers and PBMs, AI tools can be useful for tasks including claims processing, prior authorization review, and data retrieval.

American Journal

The American Journal of Managed Care

Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024

January 14, 2024

Biosimilars offer substantial promise for a new era of accessibility and affordability for patients, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential.

Pharmacy Times

Claims, Lab, and EHR Data Can Make or Break a Drug Launch

January 2, 2024

By blending claims, lab, and EHR data with payer coverage and clinical pathway data, pharma companies can gain full visibility into what’s happening in the market before they launch.

In Vivo

Worries And Hopes For Health Care Delivery In 2024

November 29, 2023

Life sciences companies will face several challenges in the new year, from more pressure on pipelines to the ongoing consequences of regulatory changes. Norstella experts share their predictions.

BioPharma Dive

Using real-world data to improve patient access to oncology therapies

October 9, 2023

Many oncology manufacturers assume that a therapy’s inclusion on clinical pathways is more important than its coverage profile, but this isn’t always true.

STAT

Drug Channels

How Payers Are Reacting to Insulin Price Changes

September 15, 2023

Insulin price caps and list price reductions are a huge step forward for patient access. But what will these changes mean for health plans?

Drug Channels

Contract Pharma

Solving Pharma’s Underlying Rebate Leakage Problem

September 13, 2023

Rebate leakage drains millions in revenue from pharma companies every year. To ensure contract compliance, manufacturers can implement these five steps.

Drug Channels

White Bagging Update 2023: Saving Money or Shifting Costs?

September 13, 2023

Buy-and-bill remains the most common distribution channel for provider-administered oncology drugs, but pharmacy channels are still significant, especially for hospital outpatient departments.

STAT

Uncovering the Patient Journey: Four Ways Real-World Data Offers Value

September 12, 2023

Infusing a commercialization strategy with real-world data provides a more holistic view of the patient journey.

Modern Healthcare

Helping payers and providers grow amid volatility: Leveraging data to improve the care experience

July 1, 2023

Preliminary data indicate that 2023 may prove to be the most volatile year for health plan enrollment in a decade.

Biopharma Dive

BioPharma Dive

Pfizer’s RSV Vaccine Wins FDA Approval in Older Adults

May 31, 2023

The shot’s clearance comes several weeks after the regulator made GSK’s Arexvy the first vaccine for RSV in the U.S.

BioPharma Dive

How Real-World Data Helps Manufacturers See the Complete Market Access Story

May 15, 2023

Over the past few decades, pharma companies have perfected the art of using market access data to support product launches, negotiate payer discounts, and secure preferred status and positioning.

Consumer Affairs

Can Anything Be Done to Bring Down Prescription Drug Costs?

May 5, 2023

The Senate Health, Education, Labor and Pensions (HELP) Committee went to work this week to find a bipartisan consensus on measures to reduce prescription drug costs.

Pharmacy Times

Pharamacy Times

Adult Vaccinations and Decentralization of Health Care: How to Navigate the Landscape

May 5, 2023

Vaccination is especially important for older adults with any chronic health conditions because vaccines can prevent serious illness and resulting complications down the road.

Drug Channels

Press Release

MMIT Announces Finalists of the Eighth-Annual Specialty Pharmacy Patient Choice Awards

April 11, 2023

Twelve specialty pharmacies recognized for their dedication to top-quality customer service.

Fierce Healthcare

Staying Competitive in an Expanding Medicare Advantage Market

March 13, 2023

By the end of 2023, more than half of the total Medicare population is expected to be enrolled in Medicare Advantage (MA), which has climbed from 25.2 million members in 2020 to 31.5 million members today.

Drug Channels

Copay Accumulator and Maximizer Update: Adoption Plateaus as Insurers Battle Patients Over Copay Support

February 22, 2023

Our latest update finds that for 2022, about 40% of commercial lives have adopted these benefit designs.

Healthline

Biosimilar Drugs to Humira Are Arriving: Why Prices Won't Be Significantly Lower

February 3, 2023

Humira, the best-selling drug used to treat multiple forms of arthritis and other conditions such as ulcerative colitis and Crohn’s disease, finally has some competition.

Drug Channels

The Evolution of Medical Benefit Contracting: How Pharma Can Prepare

January 27, 2023

Given the growth of specialty pharmaceuticals, manufacturers will need to develop more aggressive contracting strategies to secure optimal market access for their medical benefit drugs.

Formulary Watch

Analysis: Payers Restrict Medications for Autoimmune Diseases

January 26, 2023

Health insurance plans and PBMs receive poor grades for ensuring access to medications for patients living with autoimmune diseases, according to a newly released scorecard.

Drug Discovery World

What Will the 2023 Drug Discovery Landscape Look Like?

January 24, 2023

DDW Multimedia Editor Megan Thomas observes the 2023 drug discovery landscape, speaking to industry experts and looking at the foundations of 2022 on which next year will lean.

Formulary Watch

ICER Review Leads to Formulary Changes

January 17, 2023

While ICER found that overall major payer coverage policies are in line with the organization’s fair access criteria, many payers do not provide adequate transparency into clinical coverage criteria.

Drug Channels

What Pharma Companies Can Expect From the Influx of Humira Biosimilars

October 14, 2022

Next year’s staggered launch of adalimumab biosimilars will mark one of the largest losses of exclusivity for a pharmaceutical company in U.S. market history.

Fierce Pharma

How Real-World Data Can Help Maximize Patient Access

October 3, 2022

When faced with launching its new product, one midsized pharma manufacturer’s marketing team needed an innovative way to quickly identify and geographically target the right cohort of patients for their highly specialized therapy.

Fierce Healthcare

The End of the COVID-19 Public Health Emergency Is Inevitable. Here’s What That Could Mean for Health Plans

August 1, 2022

With the continuation of the COVID-19 pandemic and resulting policy changes, the health plan landscape is facing some complex challenges ahead.

PharmaExec

When Will Payers Improve Coverage of Prescription Digital Therapeutics?

July 22, 2022

New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.

Drug Channels

What Manufacturers Need to Know About Alternative Payment Models

July 15, 2022

Much has been said about healthcare’s shift from a fee-for-service model to a value-based care (VBC) model—and for good reason.

Life Science Leader

Product Launch Success: Getting It Right In Rare Disease

June 2, 2022

As we wrote in our last article, “To Ace Your Product Launch, Don’t Fail At Market Access,” launching a drug into a crowded market without understanding the market access landscape is like failing to study for a make-or-break final.

Managed Healthcare

The Oncology Care Model and Its Successor

July 14, 2022

The Oncology Care Model (OCM) was introduced in 2016 by the Centers for Medicare & Medicaid Services (CMS) in an effort to improve the quality and coordination of care for cancer patients.

Managed Healthcare

Jayne Hornung of MMIT Talks Digital Therapeutics at Asembia

May 4, 2022

The Oncology Care Model (OCM) was introduced in 2016 by the Centers for Medicare & Medicaid Services (CMS) in an effort to improve the quality and coordination of care for cancer patients.

Pharmacy Times

Understanding Reasons Behind Payers’ Slow Uptake in Digital Therapeutics

May 4, 2022

Pharmacy Times interviewed Jayne Hornung, on her presentation at the Asembia Summit 2022 on the reasons behind payers’ slow uptake on digital therapeutics despite their clearly promising benefits.

Pharmacy Times

Digital Therapeutics Show Promise, But Payer Uptake Remains Slow

May 3, 2022

Digital medicine is the use of technology to measure or intervene in certain health conditions and is overseen by the FDA, unlike digital health apps or technologies.

Specialty Pharamcy Continuum

Specialty Pharmacy Continuum

Payors Push Back on Prescription Digital Therapeutics

May 3, 2022

A software program that helps clinicians diagnose autism as early as 18 months of age, versus the three to four years required by conventional workups.

Managed Healthcare

Medicare Coverage Crucial to Prescription Digital Therapeutics: 2022 Asembia Specialty Pharmacy Summit

May 2, 2022

MMIT’s Jayne Hornung says that coverage of prescription digital therapeutics is “very slim” right now but that would likely change with Medicare coverage. And legislation to do just that has been introduced in the House and Senate.

Drug Channels

A Game-Changing Shift: Why Pharma Commercial Teams Are Turning to HEOR

April 29, 2022

As rare disease drugs and specialty therapeutics take center stage in the pharma marketplace—accounting for more than half (52%) of pharmacy spend in 2020—the ability to demonstrate a drug’s economic and clinical value to payers has become even more crucial for getting life-changing therapies into the hands of patients.

Life Science Leader

Life Science Leaders

To Ace Your Product Launch, Don't Fail At Market Access

March 1, 2022

Imagine that it’s senior year of high school, and you show up to chemistry class completely unprepared for the midterm exam — a midterm that’s worth half of your grade.

Drug Channels

Betting Big on Biosimilars: How Evolving Market Dynamics Will Impact Patient Access

January 28, 2022

While the U.S. has been frustratingly slow to embrace biosimilars, the next few years are poised to see a veritable boom in new market entrants. Only six biosimilars were available at the end of 2018.

Get an Actionable Understanding of the Business of Healthcare and Pharmaceuticals

Subscribe Today!

Get the latest news, press releases and event info from MMIT.